Click here to close now.


News Feed Item

Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results

PALATINE, IL -- (Marketwired) -- 03/03/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.

The Company reported a net loss of $3.4 million for the fourth quarter 2013 or $0.07 per diluted share, compared to net loss of $3.0 million or $0.06 per diluted share for the same period in 2012.

Research and development expenses associated with product candidates utilizing the Company's AVERSION® and IMPEDE® Technologies were $0.8 million in the fourth quarter 2013, compared to $1.2 million for the same period in 2012. Selling, marketing, general and administrative expenses were $2.8 million in the fourth quarter 2013, versus $1.8 million in the same period last year. Selling and marketing expenses for the three months ended December 31, 2013 primarily consisted of advertising and marketing activities for NEXAFED®.

For the twelve months ended December 31, 2013, Acura recorded $0.1 million in revenues compared with no revenue in the same period in 2012. These revenues were derived from the Company's sale of NEXAFED and royalties from our licensing partner on sales of Oxecta®. In the fourth quarter of 2013, the Company shipped $0.3 million of NEXAFED but because certain customers have a right of return, the Company recognized only a portion of these sales while establishing a reserve against any future potential product returns. In future periods, as the right of return no longer exists or returns can be reliably estimated, the Company will adjust this reserve.

Research and development expenses were $4.9 million in the twelve months ended December 31, 2013, compared to $3.7 million in the same period in 2012. Selling, marketing, general and administrative expenses were $8.9 million in the twelve months ended December 31, 2013, versus $6.0 million in the same period last year. The Company reported a net loss of $13.9 million or $0.29 per diluted share, for the twelve months ending December 31, 2013, compared to a net loss of $9.7 million or $0.20 per diluted share for the same period in 2012.At December 31, 2013 the Company had cash, cash equivalents and marketable securities totaling $26.1 million. During year the Company raised capital of $3.2 million from the sale of common stock on the open market and $10.0 million in term debt financing.

Conference Call Information
Acura Pharmaceuticals, Inc. will host a conference call on Tuesday, March 4, 2014 at 8:30 a.m. ET to discuss the results.

To participate in the live conference call, please dial 888-539-3612 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 8601696.

A replay of the call will be available beginning March 5, 2014 at 11:30 a.m. ET and ending on March 25, 2014 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 8601696.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXECTA® (oxycodone HC1 tablets) which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products containing other opioids.

The trademark OXECTA® is owned by Pfizer Inc.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to, our and our licensee's ability to successfully launch and commercialize our products and technologies including OXECTA® Tablets and NEXAFED® Tablets, the price discounting that may be offered by Pfizer for OXECTA®, our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies and the market acceptance of and competitive environment for any of our products, the willingness of wholesalers and pharmacies to stock NEXAFED® Tablets, expectations regarding potential market share for our products and the timing of first sales, our ability to enter into additional license agreements for our AVERSION® Technology product candidates, our exposure to product liability and other lawsuits in connection with the commercialization of our products, the increasing cost of insurance and the availability of product liability insurance coverage, the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties, and the ability of our patents to protect our products from generic competition, our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation, and the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development to meet OTC Monograph standards as applicable, the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, whether the FDA will agree with our analysis of our clinical and laboratory studies and how it may evaluate the results of these studies or whether further studies of our product candidates will be required to support FDA approval, whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and will be able to promote the features of our abuse discouraging technologies, whether our product candidates will ultimately deter abuse in commercial settings and whether our IMPEDE technology will disrupt the processing of pseudoephedrine into methamphetamine. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "indicates," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

                         ACURA PHARMACEUTICALS, INC.
                               (in thousands)

                                                    (audited)     (audited)
                                                  December 31,  December 31,
                                                      2013          2012
Current assets                                    $     27,453  $     27,996
Property, plant and equipment, net                         941         1,052
Other assets                                               236            11
  Total assets                                    $     28,630  $     29,059

Current liabilities                               $        820  $      1,424
Deferred revenue                                           287             -
Long-term debt, net of $400 of debt discount             9,600             -
Other liabilities                                            -             5
Stockholders' equity                                    17,923        27,630
  Total liabilities and stockholders' equity      $     28,630  $     29,059

                        ACURA PHARMACEUTICALS, INC.
                   (in thousands, except per share data)

                                       (audited)            (unaudited)
                                  Twelve Months Ended   Three Months Ended
                                     December 31,          December 31,
                                    2013       2012       2013       2012
  Royalty revenue                $      10  $       -  $       2  $       -
  Product sales, net                   113          -         33          -
      Total revenues, net              123          -         35          -
Operating expenses:
  Cost of sales (excluding
   write-down)                         114          -         36          -
  Inventory write-down (write-
   up)                                 250          -       (111)         -
  Research and development           4,923      3,726        803      1,208
  Selling, marketing, general
   and administrative                8,926      6,013      2,788      1,849
      Total operating expenses      14,213      9,739      3,516      3,057
      Operating loss               (14,090)    (9,739)    (3,481)    (3,057)
Non-operating income (expense):
  Investment income                    194         79         58         48
  Gain (loss) on sales of
   marketable securities                 4          -         15          -
  Other expense, net                    (9)        (8)        (9)        (7)
      Total other income
       (expense), net                  189         71         64         41
      Loss before income taxes     (13,901)    (9,668)    (3,417)    (3,016)
  Provision for income taxes             -          -          -          -
      Net loss                   $ (13,901) $  (9,668) $  (3,417) $  (3,016)
Other comprehensive income
 (loss), net of tax:
  Unrealized gains (losses) on
   securities                           59        (40)        24        (40)
      Total other comprehensive
       income (loss)                    59        (40)        24        (40)
      Comprehensive income
       (loss)                    $ (13,842) $  (9,708) $  (3,393) $  (3,056)

Loss per share:
    Basic                        $   (0.29) $   (0.20) $   (0.07) $   (0.06)
    Diluted                      $   (0.29) $   (0.20) $   (0.07) $   (0.06)
Weighted average shares
    Basic                           47,764     47,521     49,152     47,523
    Diluted                         47,764     47,521     49,152     47,523

for Acura Investor Relations
Email Contact

for Acura Media Relations
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
SYS-CON Events announced today that Spirent Communications, the leader in testing navigation and positioning systems, will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Spirent Communications enables innovations in communications technologies that help connect people. Whether it is service provider, data centers, enterprise IT networks, mobile communications, connected vehicles or the Inte...
The IoT market is on track to hit $7.1 trillion in 2020. The reality is that only a handful of companies are ready for this massive demand. There are a lot of barriers, paint points, traps, and hidden roadblocks. How can we deal with these issues and challenges? The paradigm has changed. Old-style ad-hoc trial-and-error ways will certainly lead you to the dead end. What is mandatory is an overarching and adaptive approach to effectively handle the rapid changes and exponential growth.
Who are you? How do you introduce yourself? Do you use a name, or do you greet a friend by the last four digits of his social security number? Assuming you don’t, why are we content to associate our identity with 10 random digits assigned by our phone company? Identity is an issue that affects everyone, but as individuals we don’t spend a lot of time thinking about it. In his session at @ThingsExpo, Ben Klang, Founder & President of Mojo Lingo, will discuss the impact of technology on identity....
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. Migration to cloud shifts computing resources from your data center, which can yield significant advantages provided that the cloud vendor an offer enterprise-grade quality for your application.
DevOps is gaining traction in the federal government – and for good reasons. Heightened user expectations are pushing IT organizations to accelerate application development and support more innovation. At the same time, budgetary constraints require that agencies find ways to decrease the cost of developing, maintaining, and running applications. IT now faces a daunting task: do more and react faster than ever before – all with fewer resources.
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi's VP Business Development and Engineering, will explore the IoT cloud-based platform technologies driv...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively.
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ability. Many are unable to effectively engage and inspire, creating forward momentum in the direction of desired change. Renowned for its approach to leadership and emphasis on their people, organizations increasingly look to our military for insight into these challenges.
Achim Weiss is Chief Executive Officer and co-founder of ProfitBricks. In 1995, he broke off his studies to co-found the web hosting company "Schlund+Partner." The company "Schlund+Partner" later became the 1&1 web hosting product line. From 1995 to 2008, he was the technical director for several important projects: the largest web hosting platform in the world, the second largest DSL platform, a video on-demand delivery network, the largest eMail backend in Europe, and a universal billing syste...
Electric power utilities face relentless pressure on their financial performance, and reducing distribution grid losses is one of the last untapped opportunities to meet their business goals. Combining IoT-enabled sensors and cloud-based data analytics, utilities now are able to find, quantify and reduce losses faster – and with a smaller IT footprint. Solutions exist using Internet-enabled sensors deployed temporarily at strategic locations within the distribution grid to measure actual line lo...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
The Internet of Everything is re-shaping technology trends–moving away from “request/response” architecture to an “always-on” Streaming Web where data is in constant motion and secure, reliable communication is an absolute necessity. As more and more THINGS go online, the challenges that developers will need to address will only increase exponentially. In his session at @ThingsExpo, Todd Greene, Founder & CEO of PubNub, will explore the current state of IoT connectivity and review key trends an...